文献速递糖尿病

APPL1通过抑制NFκB激活防止1型糖尿病小鼠模型中的胰腺β细胞死亡和炎症

APPL1 prevents pancreatic beta cell death and inflammation by dampening NFκB activation in a mouse model of type 1 diabetes.
PubMed 文献 · Diabetologia · 2016-12-23

研究利用Appl1敲除小鼠、野生型同窝对照及注射编码APPL1或绿色荧光蛋白的腺相关病毒的C57BL/6N小鼠,经多次低剂量链脲佐菌素诱导实验性1型糖尿病。结果显示APPL1表达在1型糖尿病小鼠胰岛及经致病性细胞因子混合物处理的胰岛中显著降低,APPL1缺失加重高血糖、β细胞丢失和胰岛炎,而β细胞特异性过表达APPL1则减轻上述表现。机制上APPL1通过抑制NFκB-iNOS-NO轴负向调控β细胞炎症和凋亡。

要点

  • APPL1在1型糖尿病小鼠胰岛及细胞因子处理的胰岛中表达显著降低。
  • APPL1缺失加重链脲佐菌素诱导的高血糖、β细胞丢失和胰岛炎,过表达则减轻。
  • APPL1通过抑制NFκB-iNOS-NO轴减少β细胞凋亡和炎症。

核心结论

  • APPL1通过抑制NFκB-iNOS-NO轴负向调控胰腺β细胞炎症和凋亡,可能是治疗1型糖尿病的潜在靶点。

研究设计与样本

  • 研究使用Appl1敲除小鼠及其野生型同窝对照,以及注射编码APPL1或绿色荧光蛋白的腺相关病毒的C57BL/6N小鼠,经多次低剂量链脲佐菌素处理诱导实验性1型糖尿病,并评估糖代谢和β细胞功能。
  • 离体评估APPL1缺失对暴露于含TNF-α、IL-1β和IFN-γ的致病性细胞因子混合物时β细胞功能的影响。

主要发现

  • APPL1表达在1型糖尿病小鼠模型胰岛及经致病性细胞因子混合物处理的胰岛中显著降低。
  • 多次低剂量链脲佐菌素诱导的高血糖、β细胞丢失和胰岛炎在Appl1基因缺失时加重,而在β细胞特异性过表达APPL1时减轻。
  • APPL1通过减少多次低剂量链脲佐菌素处理后的β细胞凋亡来维持β细胞量。
  • APPL1缺失增强致病性细胞因子混合物诱导的NFκB抑制蛋白α磷酸化及随后p65的磷酸化和转录激活,导致β细胞中NFκB调控的凋亡和促炎程序显著诱导。
  • 药理学抑制NFκB或诱导型一氧化氮合酶可大幅消除APPL1缺失对β细胞功能的有害影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Beta cell inflammation and demise is a feature of type 1 diabetes. The insulin-sensitising molecule 'adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1' (APPL1), which contains an NH2-terminal Bin/Amphiphysin/Rvs domain, a central pleckstrin homology domain and a COOH-terminal phosphotyrosine-binding domain, has been shown to modulate inflammatory response in various cell types but its role in regulating beta cell mass and inflammation in type 1 diabetes remains unknown. Thus, we investigated whether APPL1 prevents beta cell apoptosis and inflammation in diabetes. METHODS: Appl1-knockout mice and their wild-type littermates, as well as C57BL/6N mice injected with adeno-associated virus encoding APPL1 or green fluorescent protein, were treated with multiple-low-dose streptozotocin (MLDS) to induce experimental type 1 diabetes. Their glucose metabolism and beta cell function were assessed. The effect of APPL1 deficiency on beta cell function upon exposure to a diabetogenic cytokine cocktail (CKS; consisting of TNF-α, IL-1β and IFN-γ) was assessed ex vivo. RESULTS: Expression of APPL1 was significantly reduced in pancreatic islets from mouse models of type 1 diabetes or islets treated with CKS. Hyperglycaemia, beta cell loss and insulitis induced by MLDS were exacerbated by genetic deletion of Appl1 but were alleviated by beta cell-specific overexpression of APPL1. APPL1 preserved beta cell mass by reducing beta cell apoptosis upon treatment with MLDS. Mechanistically, APPL1 deficiency potentiate CKS-induced phosphorylation of NFκB inhibitor, α (IκBα) and subsequent phosphorylation and transcriptional activation of p65, leading to a dramatic induction of NFκB-regulated apoptotic and proinflammatory programs in beta cells. Pharmacological inhibition of NFκB or inducible NO synthase (iNOS) largely abrogate the detrimental effects of APPL1 deficiency on beta cell functions. CONCLUSIONS/INTERPRETATION: APPL1 negatively regulates inflammation and apoptosis in pancreatic beta cells by dampening the NFκB-iNOS-NO axis, representing a promising target for treating type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Jiang X, Zhou Y, Wu KK, et al. APPL1 prevents pancreatic beta cell death and inflammation by dampening NFκB activation in a mouse model of type 1 diabetes. Diabetologia. 2016. PMID: 28011992. doi:10.1007/s00125-016-4185-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。